SIGAL CHARLES ELLIOTT received a stock award from VIR BIOTECHNOLOGY, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 5/28/2026ACC: 0001628280-26-038966
Director
Since Jul 2020
+24K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
24K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+8K
Price / share
—
Trade value
—
% of position
25.2%
5/27/2026
31.81K→39.81K
Total
Net shares
+8K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/27/2026 | A · Award | +8K | — | — | 25.2% | 31.81K | 39.81K |
| Total | +8K | $0.00 | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
16K shares
Shares
+16K
Strike price
9.10
Held after
16K
Exercisable
—
5/27/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock16K shares | 5/27/2026 | A · Award | +16K | 9.10 | — | 16K |
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned10K
Total
10K indirect10K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 10K | Indirect |
| Total | 10K | 10K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported